MOLECULAR MARKERS IN PREDICTING THE OUTCOME OF DIFFUSE GLIOMA GRADE 4 TREATMENT
DOI:
https://doi.org/10.15407/exp-oncology.2025.02.216Keywords:
glioblastoma, MGMT, IDH1/2, temozolomideAbstract
Aim. To assess the expression of MGMT (O6-methylguanine-DNA methyltransferase) gene by MGMT RNA abundance and the presence of IDH1/2 (isocitrate dehydrogenase) variants in glioblastoma (GBM) samples for predicting the efficacy of temozolomide (TMZ) treatment, recurrence risk, and patients’ survival. Materials and Methods. The expression of the MGMT gene and the presence of IDH1/2 variants were assessed by RT-PCR in tumor samples from 39 patients with histologically verified GBM or diffuse astrocytoma, grade 4. The number of MGMT RNA copies was determined by the calibration curves based on the pMA-RQ plasmid with the inserted MGMT gene. Results. The number of MGMT RNA copies in GMB samples varied broadly from 1.7 to 88,270.2 copies per 1000 cells. The patients with a low level of MGMT expression (<1000 copies) in tumors had a more favorable prognosis for the TMZ treatment compared to the patients with a high level of MGMT RNA abundance (>10,000 copies). Among the patients included in the study, a wild type of IDH1/2 was detected in 36 cases, while 3 cases were IDH1 heterozygous. Conclusion. The level of MGMT expression is considered a significant factor for prognosing GMB patients’ survival. Patients with a low level of MGMT expression are considered candidates for efficient therapy with alkylating agents
References
Unless otherwise noted, all statistical figures have been sourced from the Central Brain Tumor Registry of the United States (CBTRUS) in CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015–2019, www.cbtrus.org. Oct. 2022.
Lee SY. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 2016;3(3):198-210. https://doi.org/10.1016/ j.gendis.2016.04.007
White K, Connor K, Clerkin J, et al. New hints towards a precision medicine strategy for IDH wild-type glioblas- toma. Ann Oncol. 2020;31(12):1679-1692. https://doi.org/10.1016/j.annonc.2020.08.2336
Louis DN, Perry A, Reifenberger G. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803-820. https://doi.org/10.1007/s00401-016-1545-1
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231-1251. https://doi.org/10.1093/neuonc/noab106
Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma.
N Engl J Med. 2005;352(10):997-1003. https://doi.org/10.1056/NEJMoa043331
Katsigiannis S, Grau S, Krischek B, et al. MGMT-positive vs MGMT-negative patients with glioblastoma: identifica- tion of prognostic factors and resection threshold. Neurosurgery. 2021;88(4):E323-E329. https://doi.org/10.1093/ neuros/nyaa562
Lazarević M, Jovanović N, Cvetković VJ, et al. A comparison of MGMT testing by MSP and qMSP in paired snap- frozen and formalin-fixed paraffin-embedded gliomas. Diagnostics (Basel). 2023;13(3):360. https://doi.org/10.3390/ diagnostics13030360
Tierling S, Jürgens-Wemheuer WM, Leismann A, et al. Bisulfite profiling of the MGMT promoter and comparison with routine testing in glioblastoma diagnostics. Clin Epigenetics. 2022;14(1):26. https://doi.org/10.1186/s13148-022-01244-4
Gibson D, Ravi A, Rodriguez E, et al. Quantitative analysis of MGMT promoter methylation in glioblastoma sug- gests nonlinear prognostic effect. Neurooncol Adv. 2023;5(1):vdad115. https://doi.org/10.1093/noajnl/vdad115
Leske H, Camenisch Gross U, Hofer S, et al. MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value. Acta Neuropathol Commun. 2023;11(1):139. https://doi.org/10.1186/s40478-023-01622-w
Gibson D, Vo AH, Lambing H, et al. A systematic review of high impact CpG sites and regions for MGMT methyla- tion in glioblastoma [A systematic review of MGMT methylation in GBM]. BMC Neurol. 2024;24(1):103. https:// doi.org/10.1186/s12883-024-03605-3
Liang BB, Wang YH, Huang JJ, et al. Genome-wide DNA methylation analysis identifies potent CpG signature for temzolomide response in non-G-CIMP glioblastomas with unmethylated MGMT promoter: MGMT-dependent roles of GPR81. CNS Neurosci Ther. 2024;30(4):e14465. https://doi.org/10.1111/cns.14465
McCornack C, Woodiwiss T, Hardi A, et al. The function of histone methylation and acetylation regulators in GBM pathophysiology. Front Oncol. 2023;13:1144184. https://doi.org/10.3389/fonc.2023.1144184
Mladek AC, Yan H, Tian S, et al. RBBP4-p300 axis modulates expression of genes essential for cell survival and is a po- tential target for therapy in glioblastoma. Neuro Oncol. 2022;24(8):1261-1272. https://doi.org/10.1093/neuonc/noac051
Gonzalez-Aponte MF, Damato AR, Trebucq LL, et al. Circadian regulation of MGMT expression and promot- er methylation underlies daily rhythms in TMZ sensitivity in glioblastoma. J Neurooncol. 2024;166(3):419-430. https://doi.org/10.1007/s11060-023-04535-9
Garrett M, Fujii Y, Osaka N, et al. Emerging roles of wild-type and mutant IDH1 in growth, metabolism and thera- peutics of glioma. In: Debinski W, editor. Gliomas [Internet]. Brisbane (AU): Exon Publications; 2021, Chapter 4. Available from: https://www.ncbi.nlm.nih.gov/books/NBK570701/
Li H, Li J, Cheng G, et al. IDH mutation and MGMT promoter methylation are associated with the pseudopro- gression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adju- vant temozolomide-based chemoradiotherapy. Clin Neurol Neurosurg. 2016;151:31-36. https://doi.org/10.1016/j. clineuro.2016.10.004
Kurdi M, Shafique Butt N, Baeesa S, et al. The impact of IDH1 mutation and MGMT promoter methylation on recurrence-free interval in glioblastoma patients treated with radiotherapy and chemotherapeutic agents. Pathol Oncol Res. 2021;27:1609778. https://doi.org/10.3389/pore.2021.1609778
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Trans- plant. 2013;48(3):452-458. https://doi.org/10.1038/bmt.2012.244
Perazzoli G, Prados J, Ortiz R, et al. Temozolomide resistance in glioblastoma cell lines: implication of MGMT, MMR, P-glycoprotein and CD133 expression. PLoS One. 2015;10(10):e0140131. https://doi.org/10.1371/journal.pone.0140131
Kitange GJ, Carlson BL, Schroeder MA, et al. Induction of MGMT expression is associated with temozolomide re- sistance in glioblastoma xenografts. Neuro Oncol. 2009;11(3):281-291. https://doi.org/10.1215/15228517-2008-090
Li Q, Ren B, Gui Q, et al. Blocking MAPK/ERK pathway sensitizes hepatocellular carcinoma cells to temozolomide via downregulating MGMT expression. Ann Transl Med. 2020;8(20):1305. https://doi.org/10.21037/atm-20-5478
Millward CP, Brodbelt AR, Haylock B, et al. The impact of MGMT methylation and IDH-1 mutation on long- term outcome for glioblastoma treated with chemoradiotherapy. Acta Neurochir (Wien). 2016;158(10):1943-1953. https://doi.org/10.1007/s00701-016-2928-8
Pandith AA, Qasim I, Baba SM, et al. Favorable role of IDH1/2 mutations aided with MGMT promoter gene methyl- ation in the outcome of patients with malignant glioma. Future Sci OA. 2020;7(3):FSO663. https://doi.org/10.2144/ fsoa-2020-0057
Alzial G, Renoult O, Paris F, et al. Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma. Onco- gene. 2022;41:613-621. https://doi.org/10.1038/s41388-021-02056-1
Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118(4):469-474. https://doi.org/10.1007/s00401-009-0561-9
Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009;15(19):6002-6007. https://doi.org/10.1158/1078-0432.CCR-09-0715
Yang P, Zhang W, Wang Y, et al. IDH mutation and MGMT promoter methylation in glioblastoma: results of a pro- spective registry. Oncotarget. 2015;6(38):40896-40906. https://doi.org/10.18632/oncotarget.5683.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
